secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001493152-25-010140
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira Pharmaceuticals develops topical Ketamir-2 for localized pain; preclinical study underway
--------------------------------------------------------------------------------

- Topical Ketamir-2 designed for slow release, enabling targeted pain relief with minimal systemic exposure.
- Preclinical study assessing efficacy of topical formulation against inflammatory pain is ongoing.
- Phase 1 oral trial for Ketamir-2 continues; Phase 2a in diabetic neuropathy planned by year-end 2025.
- First human efficacy data from Phase 2a expected in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225010140/0001493152-25-010140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225010140/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer